
May 8 (Reuters) - GRI Bio Inc GRI.O:
GRI BIO’S INTERIM BIOMARKER DATA DEMONSTRATE POSITIVE TREND TOWARDS ANTI-FIBROTIC EFFECT OF GRI-0621 IN FIRST TWELVE PATIENTS OF ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”)
GRI BIO INC - INTERIM DATA EXPECTED Q2 2025, TOPLINE DATA Q3 2025